• Total Revenue of $29.1m, +54% growth Year-on-Year
• EBITDA of $5.7m; +150% growth on 1H FY24
• EBITDA margin of 20%, increasing YoY from 12% in 1H FY24

Chrysos Corporation Ltd (ASX:C79) ('Chrysos' or the 'Company') today announces its financial results for the six months ended 31 December 2024 (1H FY25). The Company reported total revenue of $29.1m, reflecting a 54% growth year-on-year (1H FY24: $18.9m), driven by record sample volumes and significant contributions from its international units. EBITDA increased by 150% to $5.7m, with the EBITDA margin expanding to 20% from 12% in the prior corresponding period. Chrysos has signed six new lease agreements during the reporting period, bringing the total number of contracted units to 56, with 34 units currently deployed and a further 15 units ready to be shipped and installed. The Company remains focused on accelerating its deployment cadence by broadening its customer base and deepening its pipeline. Chrysos' balance sheet remains strong, with $121.9m available for growth, including $26.9m in cash and $95.0m in undrawn debt facility with CBA as at 31 December 2024.

Revenue is tracking at the lower end of the $60m to $70m guidance range, and EBITDA is tracking below the midpoint of the $9m to $19m guidance range.

Chrysos' PhotonAssay technology has continued to penetrate the global market and deliver record sample volume growth despite a subdued gold exploration spend. The Company is ready to capture any upside in the gold industry cycle through latent unit capacity and additional lease contracts.